基于CT测量的肿瘤体积对非小细胞肺癌患者新辅助化疗疗效的评估价值  

Evaluation value of neoadjuvant chemotherapy in patients with non-small cell lung cancer based on tumor volume measured by CT

作　　者：张惠玲[1] 张宏伟[1] 何元华 ZHANG Huiling;ZHANG Hongwei;HE Yuanhua(Department of Oncology,The First People's Hospital of Ziyang,Ziyang 641300,China;Department of Medical Imaging,The First People's Hospital of Ziyang,Ziyang 641300,China)

机构地区：[1]资阳市第一人民医院肿瘤科,四川资阳641300 [2]资阳市第一人民医院医学影像科,四川资阳641300

出　　处：《分子影像学杂志》2023年第3期527-531,共5页Journal of Molecular Imaging

基　　金：四川省卫生和计划生育科研课题(17PJ516)。

摘　　要：目的分析基于CT测量的肿瘤体积对非小细胞肺癌患者新辅助化疗疗效的评估价值。方法选取2019年5月~2020年5月在我院接受新辅助化疗的74例非小细胞肺癌患者,化疗后以病理结果为标准其分为有效组(n=51)和无效组(n=23),通过CT测量所有患者的肿瘤体积,并采用单因素和Logistic多因素回归分析其影响因素。结果化疗后,两组患者肿瘤体积小于化疗前(P<0.05),有效组患者肿瘤体积小于无效前(P<0.05)。两组患者化疗后6月生存率的差异无统计学意义(P>0.05);化疗后1年,有效组患者生存率高于无效组(P<0.05)。单因素分析结果显示:临床分期、分化程度以及化疗周期可能是肿瘤体积的影响因素(P<0.05)。Logistic回归分析结果显示:临床分期、分化程度及化疗周期是非小细胞肺癌患者肿瘤体积的影响因素(P<0.05)。ROC曲线分析结果表明肿瘤体积对非小细胞肺癌患者新辅助化疗疗效的预测价值,敏感度为0.732,特异性为0.800。结论基于CT测量的肿瘤体积对非小细胞肺癌患者新辅助化疗的疗效有一定的评估价值。Objective To analyze the evaluation value of neoadjuvant chemotherapy in patients with non-small cell lung cancer(NSCLC)based on tumor volume measured by CT.Methods Seventy-four patients with NSCLC who received neoadjuvant chemotherapy in our hospital from May 2019 to May 2020 were selected.After chemotherapy,they were divided into effective group(n=51)and ineffective group(n=23)based on pathological results.Tumor volume of all patients was measured by CT.Its influencing factors were analyzed by univariate and Logistic multivariate regression analysis.Results After chemotherapy,the tumor volume of 2 groups was significantly smaller than before chemotherapy(P<0.05).The tumor volume of effective group was significantly smaller than before ineffective(P<0.05).There was no significant difference in 6-month survival rate between 2 groups after chemotherapy(P>0.05).One year after chemotherapy,the survival rate of effective group was significantly higher than that of ineffective group(P<0.05).Univariate analysis showed that clinical stage,degree of differentiation and chemotherapy cycle were influencing factors of tumor volume(P<0.05).Logistic regression analysis showed that clinical stage,differentiation degree and chemotherapy cycle were the influencing factors of tumor volume in patients with NSCLC(P<0.05).ROC curve analysis showed that the sensitivity and specificity of tumor volume in predicting the efficacy of neoadjuvant chemotherapy in NSCLC patients were 0.732 and 0.800.Conclusion Tumor volume measured by CT has certain value in evaluating the efficacy of neoadjuvant chemotherapy in patients with NSCLC.

关 键 词：CT 肿瘤体积 非小细胞肺癌 新辅助化疗 评估 

分 类 号：R734.2[医药卫生—肿瘤]